GPR52 Modulator Compounds for Neurological Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved modulator compounds for GPR52, a G-protein coupled receptor, to effectively treat various neurological conditions as existing solutions are inadequate in addressing the complexities of these diseases.
Innovation Solution
The development of compounds of Formula (I) and their pharmaceutically acceptable salts, which are designed to modulate GPR52 activity, are administered to patients to treat a range of neurological disorders, including schizophrenia, Parkinson's disease, and Alzheimer's Disease, by targeting specific receptor sites and pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing modulator compounds are used for GPR52, then some neurological conditions can be treated, but the treatment effectiveness is inadequate and symptoms are not sufficiently ameliorated
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of GPR52 modulator compounds. Formula (I) presents a generalized molecular structure with multiple variable parameters (R1-R10 substituents, X/Y heteroatoms, Q nitrogen or carbon) that can be adjusted to optimize binding affinity and selectivity for GPR52, thereby improving treatment effectiveness while addressing diverse neurological condition complexities
Solution Approach 2:
The patent employs composite materials principles by creating compounds with complex multi-component molecular structures. Formula (I) integrates multiple functional groups, heteroatoms, and substituent patterns that work synergistically to enhance modulator activity against GPR52, providing improved therapeutic efficacy for neurological disorders through composite molecular design
2Reliability
If compounds of Formula (I) are developed with multiple substituent options, then treatment effectiveness improves, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex GPR52 modulator into distinct structural modules within Formula (I). The molecule is segmented into core framework elements (X, Y, Q positions) and variable substituent regions (R1-R10 groups), allowing independent optimization of each segment's properties to achieve therapeutic effectiveness while managing overall molecular complexity through modular design
Solution Approach 2:
The patent implements local quality by assigning specific functional properties to different regions of the molecular structure. Each substituent position (R1-R10) can be independently tailored with specific chemical groups to optimize local interactions with GPR52 binding sites, thereby enhancing therapeutic benefit while controlling complexity through localized functional optimization rather than uniform molecular complexity
Data Source
AI summary
The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.